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Abstract
Background:  Protease inhibitors, particularly ritonavir, causes significant gastrointestinal
disturbances such as nausea, even at low doses. This ritonavir-induced nausea could be related to
its oxidative stress in the gut. Alleviation of drug-induced nausea is important in effectively
increasing patients' compliance and improving their quality of life. Conventional anti-emetic drugs
can only partially abate the symptoms in these patients, and their cost has also been a concern. Rats
respond to nausea-producing emetic stimuli by increasing consumption of non-nutritive substances
like kaolin or clay, a phenomenon known as pica. In this study, we used this rat pica model to
evaluate the effects of Scutellaria baicalensis, a commonly used oriental herbal medicine, on
ritonavir-induced nausea.
Results: Rats treated with 20 mg/kg ritonavir significant caused increases of kaolin consumption
at 24 to 48 hr (P  < 0.01). Pretreatment with 0.3 and 3 mg/kg Scutellaria baicalensis extract
significantly decreased ritonavir-induced kaolin intake in a dose-related manner (P  < 0.01).
Compared to vehicle treatment, the extract completely prevented ritonavir-induced kaolin
consumption at dose 3 mg/kg. The area under the curves (AUC) for kaolin intake from time 0 to
120 hr for vehicle only, ritonavir only, SbE 0.3 mg/kg plus ritonavir, and SbE 3 mg/kg plus ritonavir
were 27.3 g•hr, 146.7 g•hr, 123.2 g•hr, and 32.7 g•hr, respectively. The reduction in area under the
curves of kaolin intake from time 0 to 120 hr between ritonavir only and SbE 0.3 mg/kg plus
ritonavir, ritonavir only and SbE 3 mg/kg plus ritonavir were 16.0% and 77.7%, respectively.
Conclusion:  Scutellaria baicalensis significantly attenuated ritonavir-induced pica, and
demonstrated a potential in treating ritonavir-induced nausea.
Introduction
HIV infection/AIDS is a deadly disease that has affected
over 30 million people world-wide and at least a million
people in this country [1]. To achieve the treatment goal
of reduction in viral loads and improved life expectancy,
the treatment guidelines entail that patients be highly
compliant to the drug regimens for an extended period of
time [2,3]. However, the main obstacle that dissuades the
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patient from the goal is medication-induced side effects
[2]. These side effects not only cause deterioration of the
quality of life, but also have a major negative impact on
compliance [4]. Nausea/vomiting is one such significant
medication-related side effect that has been widely
reported [5-10].
Protease inhibitor is a commonly used class of anti-HIV
drugs [11,12]. Protease inhibitors, especially ritonavir,
however, cause significant gastrointestinal disturbances,
such as nausea/vomiting [7,8,11]. Although ritonavir can
be used as a protease inhibitor by itself, it produces
numerous side effects at the doses needed for an anti-viral
effect, and thus it is poorly tolerated. Often ritonavir is
used at a low dose to "boost" the drug levels of other pro-
tease inhibitors. Even at low doses, patients still could
have ritonavir induced gastrointestinal side effects, espe-
cially nausea [12-14]. The incidence of ritonavir induced
nausea/vomiting is approximately 23%, significantly
higher than other antiretroviral agents [15]. Thus, allevia-
tion of ritonavir-induced nausea could improve patients'
compliance and their quality of life. Conventional anti-
emetic drugs can only partially abate the symptoms in
these patients, and their cost has also been a concern [16].
Rats react to nausea/vomiting stimuli by altered feeding
habits, manifested as increased consumption of non-
nutritive substances like kaolin (a type of clay), known as
pica [17-20]. We previously demonstrated a significant
anti-nausea (anti-pica) effect of anti-oxidant herbal med-
icines, i.e., Scutellaria baicalensis and ginseng, in cisplatin-
induced pica in rats [21,22]. It has been shown that riton-
avir caused endothelial cell cytotoxicity and oxidative
stress, and this oxidative stress could be a mechanism of
ritonavir-induced tissue dysfunction [23,24]. In this
study, we used a rat model to investigate the role of anti-
oxidant herb, S. baicalensis extract (SbE) in decreasing
ritonavir-induced nausea.
Methods
Animals
The experimental protocol was approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the
University of Chicago. Male Wistar strain rats (Harlan
Sprague Dawley, Indianapolis, IN), weighing between
150–300 g, were used in this study. Animals were housed
in standard isolation cages (45 cm × 35 cm × 25 cm) in
environmentally controlled conditions with 12 hr light /
12 hr dark cycle. Rats were allowed free access to water,
standard laboratory rat chow (Harlan-Teklad, Madison,
WI) and kaolin (see below), placed in separated contain-
ers continuously available throughout the experiment.
Preparation and analysis of S. baicalensis extract (SbE)
S. baicalensis was obtained from a single batch from the
Beijing Chinese Herbal Medicine Company. Voucher
specimen was deposited in our laboratory at the Tang
Center for Herbal Medicine Research, University of Chi-
cago. The herbal sample was tested by Applied Consumer
Services (Hialeah Gardens, FL), and it has been confirmed
that the sample is free from contaminants such as micro-
organisms, pesticide residues, and toxic elements.
The root of S. baicalensis was soaked in cold water for 2 hr,
and then cut into small pieces (less than 2 mm). These
pieces were treated with hot water (approximately 95°C)
for 1 hr. The filtrate obtained following the hot water
treatment was evaporated under vacuum and lyophilized.
During the experiment, the dried powder was dissolved in
balanced salt solution (BSS), and centrifuged for 5 min
(1,200 rpm). The supernatant was used.
The extract was analyzed by liquid chromatography/mass
spectrometry (LC/MS, Hitachi M1000, Hitachi Denshi,
Ltd., Japan) with Atmospheric Pressure Chemical Ioniza-
tion interface. The extract was dissolved in deionized
water at a concentration of 1 mg/ml. The mobile phase
was 14 mM ammonium acetate in acetonitrite (v/v:1/99)
and flow rate was 0.8 ml/min. The sample (150 µl solu-
tion) was injected. The system was calibrated with fla-
vopiridol. The extract contained the following flavones:
wogon (51.5%), baicalein (35.6%), skullcapflavone I
(4.8%), and skullcapflavone II (8.3%) (Figure 1) [25].
Kaolin preparation
Kaolin was prepared based on the method described pre-
viously [21]. Briefly, pharmacological grade kaolin (or
hydrated aluminum silicate; Fisher, Fair Lawn, NJ) and
acacia (or Gum Arabic; Fisher, Fair Lawn, NJ) were mixed
Structures of four major constituents isolated from Scutellaria  baicalensis roots Figure 1
Structures of four major constituents isolated from Scutellaria 
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using a 99:1 ratio. Distilled water was used to form a thick
paste of this mixture. The paste was rolled and cut into
pieces that resembled regular rat chow pellets. The pellets
were dried at room temperature for 72 hr.
Experimental protocol
Rats placed in individual cages were allowed access to
both regular food and kaolin during the 3-day adaptation
period prior to study period. Rats then received ritonavir
in the morning on 2 consecutive days (0 and 24 hrs) by
oral gavage [26-28]. SbE and baicalein pretreatments were
administered intraperitoneally [21], 30 min prior to each
ritonavir administration. Rats were observed immediately
and at 2 hr to ensure that animals are not distressed and
they are comfortable.
During the experiment, kaolin and food pellets was
weighed to the nearest 0.1 g and replaced in the containers
every morning at the same time after collecting the
remaining kaolin and food from the previous day. Kaolin
and food intake was measured every 24 hr for 5 days.
The animals did not demonstrate any signs of adverse
effects such as restlessness or respiratory distress following
test administrations.
Statistical analysis
Data were analyzed using a two-way analysis of variance
(ANOVA) with group and time as the two factors. Statisti-
cal significance was considered at P < 0.05.
Results
Rats treated with vehicle (normal saline) only consumed
less than 1 g/day of kaolin during the consecutive 5 days
(0, 24, 48, 72, 96, 120 hr), indicating that saline does not
obviously induce pica (Figure 2). Figure 2 also showed
effects of ritonavir on kaolin intake. Ritonavir doses at 5,
10 and 20 mg/kg significant caused increases of kaolin
consumption at 24 to 48 hr in a dose-related manner (P <
0.01). Increasing ritonavir dose to 30 mg/kg did not fur-
ther increase kaolin intake, suggesting toxic effect at
higher ritonavir dose. This possible toxic effect was sup-
ported by the fact that at 30 mg/kg, ritonavir significantly
reduced food intake at 24 to 48 hr (P < 0.05; Figure 3).
Based on these results, we selected 20 mg/kg ritonavir
dose for evaluation of herbal effects on the drug-induced
pica.
Figure 4 demonstrated that pretreatment with SbE signifi-
cantly decreased ritonavir-induced kaolin intake in a
dose-related manner (P  < 0.01). Compared to vehicle
treatment, SbE at dose 3 mg/kg completely prevented
ritonavir-induced kaolin consumption. The area under
the curves (AUC) for kaolin intake from time 0 to 120 hr
for vehicle only, ritonavir only, SbE 0.3 mg/kg plus riton-
avir, and SbE 3 mg/kg plus ritonavir were 27.3 g•hr, 146.7
g•hr, 123.2 g•hr, and 32.7 g•hr, respectively. The reduc-
tion in AUC of kaolin intake between ritonavir only and
SbE 0.3 mg/kg plus ritonavir, ritonavir only and SbE 3
mg/kg plus ritonavir were 16.0% and 77.7%, respectively.
Food intake was not affected significantly in all these
groups.
In addition, when SbE 3 mg/kg was administered alone,
the extract did not affect kaolin consumption and food
intake.
Discussion
Typically, AIDS patients are treated with combinations of
different drug groups to achieve the therapeutic goals of
reduced viral loads and improved life expectancy [1].
Potent as these drugs may be, they are certainly not free
from side effects [1], and thus add a challenging dimen-
sion to the management of drug-related adverse reactions.
Patient adherence to the therapeutic regimen is of vital
importance, as non-adherence can result in reduced sup-
pression of viral load and also development of drug resist-
ance [29]. Adherence of more than or equal to 95% is
required to maintain control over viral replication, but in
reality, the adherence rate is often lower with most studies
showing that 40–60% of patients are less than 90% adher-
ent [3]. Apart from other causes, drug-induced side effects
are greatly responsible for poor patient compliance. Fre-
quency and severity of side effects was one of the primary
barriers to adherence, with nausea/vomiting topping the
list of side effects [2]. Thus, any step towards improving
Effect of ritonavir (mg/kg) on kaolin intake in rats Figure 2
Effect of ritonavir (mg/kg) on kaolin intake in rats. Ritonavir 
doses at 5, 10 and 20 mg/kg induced significant increases of 
kaolin intake at 24 and 48 hr (P < 0.01), while 30 mg/kg did 
not further increase kaolin intake. NS = normal saline.AIDS Research and Therapy 2005, 2:12 http://www.aidsrestherapy.com/content/2/1/12
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patients' adherence to the drug regimen is vital for success-
ful management of the disease.
The mechanism by which ritonavir causes nausea has not
been investigated. Protease inhibitors cause premature
cardiovascular diseases [23,30]. It has been shown that
ritonavir induced cytotoxicity of human endothelial cells
[23,30]. Conklin et al. [24] investigated the effects of
ritonavir on vascular endothelial cell function in porcine
carotid arteries. Superoxide and nitrotyrosine levels were
measured. They observed that endothelium-dependent
vasorelaxation was significantly reduced in ritonavir-
treated vessels compared to controls. There were signifi-
cant increases in basal and NADPH-stimulated superox-
ide production in vessel rings treated with ritonavir
compared to control vessels. Dihydroethidium staining
and nitrotyrosine staining were also elevated in endothe-
lial cells of ritonavir-treated vessels, indicating increased
superoxide production and increased oxidative stress,
respectively, in ritonavir-treated vessels compared to con-
trols. Their data demonstrated that increased oxidative
stress could be a mechanism of ritonavir-induced cellular
dysfunction.
In addition to ritonavir, nausea/vomiting is also associ-
ated with a number of other commonly prescribed drugs
in AIDS pharmacotherapy [31,32]. A combination anti-
retroviral therapy is advocated for initial treatment of
established AIDS cases [1], and this multi-pharmacy
increases the likelihood of emesis. Additionally, AIDS-
related CNS disorders, gastroparesis, autonomic neuropa-
thy and secondary infections can further aggravate drug-
induced emesis [33]. Thus, anti-emetic use may have a
wider scope in the management of AIDS patients, beyond
ritonavir-induced nausea.
S. baicalensis is a widely used herb in traditional medical
systems of China and Japan [34,35]. The dried root has
been used clinically for allergies, inflammatory diseases,
hyperlipidemia, and arteriosclerosis [34]. We previously
observed that SbE attenuated cisplatin-induced emesis in
rats. [34]. The major constituents in SbE are flavonoids, a
group of polyhydroxy phenols [36]. These flavonoids,
such as baicalein (Figure 1), possess anti-oxidant and
other effects, which could also potentially be used to
boost immune responses in HIV patients [37].
Several in vivo and in vitro studies have demonstrated the
anti-oxidant capabilities of SbE. Kimuya et al. [36] and
Kimura et al. [34] reported that liver homogenates of rats
who were orally administered SbE, baicalein, and
wogonin were resistant to lipid peroxidation. Gabrielska
et al. [38] showed that an extract of SbE reduced lipo-
somal lipid peroxidation. In a similar study, Gao et al.
[39] observed that baicalein administration inhibited
iron-dependent lipid peroxidation in rat liver micro-
somes. Subsequently, Gao et al. [40] showed that bai-
calein prevented cell death in fibroblasts damaged by
H2O2, tetra-butyl hydroperoxide, and superoxide anions.
Hamada et al. investigated in vitro radical scavenging effect
of baicalein, and quantified superoxide and hydroxyl rad-
ical-scavenging effect by electron spin resonance spec-
trometry [41]. They reported that in a hypoxanthine-
xanthine system, baicalein strongly reduced superoxide
radicals. Our laboratory has reported that SbE dose-
Effects of pretreatment with Scutellaria baicalensis extract  (SbE, mg/kg) on kaolin intake induced by ritonavir in rats Figure 4
Effects of pretreatment with Scutellaria baicalensis extract 
(SbE, mg/kg) on kaolin intake induced by ritonavir in rats. 
Increased kaolin intake induced by ritonavir (mg/kg) was 
decreased with SbE pretreatment in a dose-related manner 
(P < 0.01). NS = normal saline.
Effects of ritonavir (mg/kg) on food intake in rats Figure 3
Effects of ritonavir (mg/kg) on food intake in rats. There was 
a significant reduction in food intake following 30 mg/kg 
ritonavir treatment at 24 and 48 hr (P < 0.05). NS = normal 
saline.AIDS Research and Therapy 2005, 2:12 http://www.aidsrestherapy.com/content/2/1/12
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dependently attenuated effects of reactive oxygen species
(ROS) in cardiomyocytes [25].
Ritonavir is known to induce nausea in significant
number of AIDS patients [7,8,12,14] but has not been
studied in an animal model. In this study, we observed
that SbE attenuated kaolin intake or pica in ritonavir-
treated rats. Our data support the hypothesis that ritona-
vir-induced emesis is related to its oxidative stress in the
gut, and anti-oxidant herbs may have a therapeutic poten-
tial in ritonavir-induced emesis in AIDS patients.
An advantage of botanical therapies is the reduction of
healthcare cost. With expensive anti-AIDS therapy, effica-
cious herbal products will bring down the cost of care,
while providing the patient with relief from drug-induced
side effects and improving their quality of life. AIDS
patients are known to use herbal products more often
than the general populace [1,42], and evidence-based
herbal therapies can offer them with a practical alterna-
tive. Thus, systematic herbal evaluation, including con-
ducting controlled clinical trials, is important in offering
options to conventional pharmacological treatment [43].
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